Durham, NC (PRWEB) October 05, 2012
AlphaMed Press has been named a 2012 MM&M Award finalist in the category of Best Mobile App for Healthcare Professionals, for The Oncologist HD App. The MM&M Awards recognize the most creative communications in the pharmaceutical industry.
After two comprehensive rounds of scoring by a panel of over 100 selected leaders in the healthcare marketing community, five finalists have been selected for each of the MM&M Awards categories. Best Mobile App for Healthcare Professionals is one of the awards’ newest categories, exemplifying a cultural shift in how information is consumed and how new technologies can be utilized in healthcare.
“We are very excited to be a finalist in this exciting new category. We created an application to provide more compelling, rich-media content ultimately offering additional opportunities to translate cancer research into practice for our readers across the globe,” said Marty Murphy, Vice President, Publishing Technology & Business Development.
The Oncologist HD app goes beyond simply providing a version of the trusted print publication and its archive of peer-reviewed content. It is supplemented with engaging features that enhance the user experience, provide convenient channels for peer-to-peer interaction, and deliver on-demand educational activities, all at no cost to the user.
Gold and silver winners will be announced on October 9 at The MM&M Awards 2012 Awards dinner and ceremony. (Click here for a full list of all finalists.)
# # #
About AlphaMed Press:
Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. . STEM CELLS® (http://www.StemCells.com), celebrating its 30th anniversary in 2012, is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com), entering its 17th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com), in its inaugural year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.